Luke Halpern, Associate Editor

High pneumococcal community-acquired pneumonia burden in older adults highlights the critical role of pharmacists in driving 21-valent vaccine uptake and patient-centered prevention strategies.

Pharmacists play a central role in shared decision-making by guiding patients through lipid-lowering options, cost considerations, and ongoing monitoring aligned with updated dyslipidemia guidelines.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

New data highlight the impact of pharmacist-driven continuous glucose monitoring services on hemoglobin A1C reduction, time in range, and medication adherence.

Risk-based screening, early symptom recognition, and patient engagement can help pharmacists detect chronic kidney disease and prevent progression.

Pharmacists can improve statin adherence and refine triglyceride management by leveraging patient-centered counseling, adherence strategies, and updated guideline recommendations prioritizing statins and targeted adjunctive therapies.

Jennifer Goldman, PharmD, highlights clinical trial data and practical strategies for pharmacists to support initiation, adherence, and adverse effect management with tirzepatide at the American Pharmacists Association Annual Meeting and Exposition.

Keith Bellovich, DO, explains how SARS-CoV-2–driven inflammation contributes to kidney injury and may reveal previously undiagnosed chronic kidney disease.

Pharmacists play a central role in implementing new dyslipidemia guidelines, including ApoB testing, earlier risk assessment, and expanded use of combination lipid-lowering therapy.

New analysis suggests oral semaglutide may offer improved efficacy and tolerability compared with orforglipron, informing treatment selection in an increasingly competitive oral GLP-1 landscape.

The first-in-class triple agonist met all primary and key secondary end points in the TRANSCEND-T2D-1 trial.

Joseph Saseen, PharmD, addresses statin intolerance and misinformation and provides a look at aggressive new LDL targets and emerging therapies not yet captured in the 2026 guidelines.

AHA Epidemiology Sessions 2026 show that chronic kidney disease (CKD) proteinuria drops of 30% or more cut heart failure, major adverse cardiovascular events, and death, a key prevention signal.

Deucravacitinib offers a targeted, well-tolerated oral option for patients with psoriatic arthritis, with efficacy comparable to biologics and meaningful benefits in patient-reported outcomes.

The updated dosing schedule for nusinersen offers increased drug exposure and may further improve outcomes for patients with spinal muscular atrophy.

There was limited evidence supporting additional clinical benefits.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

Clinical pharmacist specialists emphasized the pharmacist's role closing the gap between guideline recommendations and patient access to CGMs and automated insulin delivery.

From a pipeline exploding with oral and injectable options to emerging evidence in liver disease, substance use disorder, and kidney disease, Emily Eddy, PharmD, laid out the full scope of incretin therapy's expanding reach at APhA2026.

New data show that pharmacist-led interventions in independent community pharmacies can move the needle on A1C, blood pressure, and stroke risk, even in rural and underserved settings.

At APhA 2026, Damika Walker, PharmD, RPh, argued that closing stubbornly low adult vaccination rates requires a shift in how pharmacists approach every patient encounter.

With updated recommendations for adults aged 50 and older, pharmacy teams are uniquely positioned to bridge gaps in care through community engagement and proactive clinical assessments.

In a session at the American Pharmacists Association Annual Meeting, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, provided practical insights for pharmacists to optimize the care of patients with cardio-kidney-metabolic conditions.

Joseph Saseen, PharmD, explains the 2026 dyslipidemia guidelines' push for universal lipoprotein A screening, clarifies when apolipoprotein B testing adds value, and outlines how new FDA-approved therapies fit into the updated lipid-lowering treatment algorithm.

Insulin icodec-abae injection becomes the first and only once-weekly basal insulin option, offering personalized care for adults with type 2 diabetes (T2D).

Jacinda “JAM" Abdul-Mutakabbir, PharmD, MPH, discusses the adult burden of respiratory syncytial virus (RSV) and the critical role of pharmacists in vaccine access and education—especially for marginalized populations.

The approval is a milestone for rare disease that has lacked treatments capable of crossing the blood-brain barrier and introduces a new class of agent that pharmacists will need to understand.

Craig Beavers urges pharmacists to engage with obstructive hypertrophic cardiomyopathy (oHCM) management and explains how the alignment between mavacamten's clinical trial data and real-world outcomes validates its role as a safe, effective, and sustainable long-term therapy.

Swapping 30 minutes of teen sedentary time for vigorous activity or extra sleep cuts insulin resistance by 15%, aiding type 2 diabetes (T2D) prevention.

Joseph Saseen, PharmD, breaks down how the new PREVENT ASCVD calculator improves on its predecessor and what the expanded LDL-C goal framework means for treatment decisions in pharmacy practice.